148 related articles for article (PubMed ID: 17593519)
1. Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.
Karube M; Nakabayashi K; Fujioka Y; Yoshihara K; Yamada A; Matsunaga A; Saito T
Clin Exp Nephrol; 2007 Jun; 11(2):174-179. PubMed ID: 17593519
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC
Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
[TBL] [Abstract][Full Text] [Related]
3. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
[TBL] [Abstract][Full Text] [Related]
5. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy.
Oikawa S; Suzuki N; Sakuma E; Saito T; Namai K; Kotake H; Fujii Y; Toyota T
Am J Kidney Dis; 1991 Nov; 18(5):553-8. PubMed ID: 1951334
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
Tokura T; Itano S; Kobayashi S; Kuwabara A; Fujimoto S; Horike H; Satoh M; Komai N; Tomita N; Matsunaga A; Saito T; Sasaki T; Kashihara N
J Atheroscler Thromb; 2011; 18(6):536-41. PubMed ID: 21467726
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U
Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
[TBL] [Abstract][Full Text] [Related]
8. Type III hyperlipoproteinemia in a child with hemolytic uremic syndrome.
Feussner G; Wingen AM; Ziegler R
Metabolism; 1990 Nov; 39(11):1196-9. PubMed ID: 2233282
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
10. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Nissen H; Hansen TS
Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
[TBL] [Abstract][Full Text] [Related]
11. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
12. Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.
Sakuma N; Hibino T; Saeki T; Nagata T; Sato T; Okuda N; Matsunaga A; Sasaki J
J Atheroscler Thromb; 2014; 21(9):983-8. PubMed ID: 24953047
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
14. A case of lipoprotein glomerulopathy successfully treated with probucol.
Amenomori M; Haneda M; Morikawa J; Nishigaki I; Maeda S; Hidaka H; Kikkawa R; Shigeta Y
Nephron; 1994; 67(1):109-13. PubMed ID: 8052351
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant.
Feussner G; Albanese M; Valencia A
Atherosclerosis; 1996 Oct; 126(2):177-84. PubMed ID: 8902143
[TBL] [Abstract][Full Text] [Related]
16. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
[TBL] [Abstract][Full Text] [Related]
17. A case of lipoprotein glomerulopathy. Light and electron microscopic observations of the glomerulus.
Shibata T; Kaneko N; Hara Y; Saito T; Sakaguchi H
Acta Pathol Jpn; 1990 Jun; 40(6):448-57. PubMed ID: 2392939
[TBL] [Abstract][Full Text] [Related]
18. [Familial type III hyperlipoproteinemia].
Eto M; Saito M
Nihon Rinsho; 2013 Sep; 71(9):1590-4. PubMed ID: 24205719
[TBL] [Abstract][Full Text] [Related]
19. Apo E variants in patients with type III hyperlipoproteinemia.
Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of type III hyperlipoproteinemia in Germany.
Feussner G; Feussner V; Hoffmann MM; Lohrmann J; Wieland H; März W
Hum Mutat; 1998; 11(6):417-23. PubMed ID: 9603433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
